The Johns Hopkins University was awarded a Cooperative Agreement from the National Center for Advancing Translational Sciences (NCATS), a program of the National Institutes of Health (CFDA 93.350), in the amount of $9,740,327.00 starting on May 15, 2024 and running through Apr 30, 2031. The award supports the Johns Hopkins Institute for Clinical and Translational Research, which conducts a diverse range of clinical and translational science projects to accelerate the translation of scientific...
The National Institute of Nursing Research (NINR) has awarded a $262,880 Project Grant under the Nursing Research federal grant program (CFDA 93.361) to The Johns Hopkins University. The grant, titled "The Johns Hopkins Nursing Science Incubator for SDOH Solutions (N-SISS): Preparing Innovators to Eliminate Health Inequities and Redesign Health," aims to support nurse scientists and researchers in related fields in developing innovative, equity-focused research programs addressing...
This federal Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes program (CFDA 93.226) provides $308,016 to The Johns Hopkins University to conduct a multi-faceted analysis of the lung cancer diagnostic process. The goal is to characterize the patient journey, measure delays, identify associated harms and health disparities, and pinpoint obstacles that impact diagnostic performance and patient outcomes. The...
The Department of Health and Human Services' Food and Drug Administration awarded The Johns Hopkins University a $3.2 million Project Grant under the FDA Research program (CFDA 93.103) for the period of September 15, 2022 through August 31, 2026. The grant aims to improve clinical trials for Ataxia Telangiectasia (A-T), a rare genetic disease, through three specific objectives: prospectively testing A-T severity stratification using genetic, phenotypic and laboratory markers; using RNA...
The Johns Hopkins University was awarded a $1,000,000 Cooperative Agreement under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program by the Agency for Healthcare Research and Quality (AHRQ). The award, titled "Supporting Patients Recovering from COVID-19 (SPARC)," will fund a comprehensive, multidisciplinary program to deliver long-term care to patients with Long COVID. Key objectives include: Expanding the existing Johns Hopkins Post-Acute COVID-19 Team (JH...
The Johns Hopkins University was awarded a $4,691,464 Project Grant from the Department of Health and Human Services Health Resources and Services Administration Bureau of Health Professionals under the Public Health Training Centers Program (CFDA 93.516). The grant will fund the HEAL (Health Educators, Advocates, and Leaders) Training program to address healthcare gaps in Baltimore City through community health worker training. Specifically, the program will develop a novel curriculum to...
This $600,000 Project Grant award under the Maternal and Child Health Federal Consolidated Programs (CFDA 93.110) from the Health Resources and Services Administration (HRSA) supports maternal and child health research conducted by The Johns Hopkins University in Baltimore, MD. The award, effective July 1, 2024 through June 30, 2027, will fund sophisticated services to HRSA such as research, clinical trials, data analysis, technological innovation, and specialized consultation across multiple...
The Johns Hopkins University was awarded a $5,265,843 Project Grant from the U.S. Department of Education's Office of Elementary and Secondary Education under the Education Innovation and Research (EIR) program (CFDA 84.411). The grant, which runs from January 1, 2025 to December 31, 2029, will support the development, implementation, and evaluation of innovative educational interventions designed to improve student achievement and attainment, particularly for high-need students, in middle and...
The U.S. Department of Defense's Defense Health Agency awarded a $1,738,924 Project Grant to The Johns Hopkins University to conduct research on "Proteomics of Atrioventricular Septal Defect in Down Syndrome" from September 1, 2024 through August 31, 2028. This research, funded under the Military Medical Research and Development program (CFDA 12.420), aims to advance scientific understanding and treatment of this condition impacting military members, veterans, and their families. The...
This Cooperative Agreement award, provided by the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103), supports Duke University's efforts to collaborate with the FDA on critical public health topics related to the agency's oversight of medical products, policies, and surveillance systems. The $700,000 award, with a performance period from September 2024 to August 2029, will enable Duke...